Introduction
Vascular calcification (VC), the pathological calcification of cardiovascular structures, is one of the most important factors determining patients' mortality around the world. Although different mechanisms on pathogenesis of vascular calcification have been proposed, 1 our understanding of the calcification pathogenesis is far from complete. However, in recent years, some risk factors are emerging, including elevated serum phosphorus and defective synthesis of pyrophosphate. 2 The presence of calcium phosphate crystals (CPCs) in blood vessels ( Figure 1) , myocardium, cardiac valves, and others soft tissues is considered a pathological or ectopic calcification. 1 However, the accumulation of CPC in hard tissues (such as bone and teeth) is considered a physiological process. In blood vessels, calcified deposits are found in distinct layers of the aortic wall. Intimal calcification occurs in atherosclerotic lesions, whereas medial calcification (socalled Monckeberg's medial sclerosis) occurs in medial layer of the aortic wall and is associated with elastic lamin. 2 The physicochemical process of CPC formation is similar both in hard (bone) and soft tissues (vessels). However, in physiological conditions, CPC deposition is enhanced or inhibited depending of each tissue.
Elevated serum phosphate and vascular calcification
During the past decade, elevated serum phosphate has emerged as a key risk factor for VC in general population and in patients with chronic kidney disease. 3 The balance between phosphate absorption from intestine, mobilization from bone, and urinary excretion determines the final serum phosphate levels. Several diseases have been correlated with dysregulation of phosphate homeostasis, including hyperparathyroidism, vitamin D (hyper-and hypovitaminosis), chronic renal disease, osteoporosis, and diabetes mellitus. 3 Treatment of hyperphosphatemia with phosphate binders is associated with slow progression of cardiovascular calcification in haemodialysis patients. 4 In biological systems, phosphate is found in hard tissues (85%), soft tissues (14%), and in extracellular fluid (1%). In extracellular fluid, 85% exists as a free phosphate ion in solution, which is called inorganic phosphate (Pi). The remaining is protein bound and 5% is complexed with cations such as (Ca 2+ , Mg 2+ , and Na 2+ ). Aqueous
Pi exists in four forms according to it triprotic equilibrium ( Figure 2 Figure 2 ).
The final product of calcium phosphate salts reaction is hydroxyapatite (Ca 10 (PO 4 ) 6 (OH)), the main component of bone. Hydroxyapatite, and two of its precursors (amorphous calcium phosphate and octocalcium phosphate), is found in calcified aorta. 5 Moreover, the Mg-substituted b-tricalcium phosphate form, called whitlockite, is also found in calcified aortas. 6 
Extracellular pyrophosphate reduction and vascular calcification
Extracellular fluids (such as urine, serum, and synovial fluids) are supersaturated with phosphate and calcium, resulting in a tendency for spontaneous calcium phosphate precipitation. To prevent passive deposition of CPC the body synthesized inhibitors of calcification, including proteins (Matrix Gla Proteins, Fetuin A, and osteopontin) and inhibitors of low molecular weight such as pyrophosphate. 1 Extracellular pyrophosphate (PPi) is a potent endogenous inhibitor of hydroxyapatite formation both in vitro 7 and in vivo. In haemodialysis patients, plasma PPi is reduced by 32% after standard haemodialysis 8 and leads to excessive vascular calcification in the medial layer of the aortic wall. Pyrophosphate is degraded to Pi by tissue non-specific alkaline phosphatase (TNAP) in extracellular fluids ( Figure 2) . Tissue nonspecific alkaline phosphatase activity is increased in models of medial
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vascular calcification, such as in uremic rats 9 or in a mouse model of
Hutchinson-Gilford progeria syndrome. 2 Moreover, PPi is produced by ectonucleotide pyrophosphatase/phosphodiesterase (eNPP), which hydrolyses extracellular adenosine-5 ′ -triphosphate (ATP) to generate PPi and AMP (see Figure 2) . In vascular smooth muscle cells (VSMCs) and in aorta, hydrolysis of extracellular ATP by eNPP1 is the main source of extracellular PPi. 10 Mutations in eNPP1 result in generalized arterial calcification during infancy, which is characterized by artery calcification in humans. 1 In addition, it has recently been shown that ATP plays an important role in prevention of vascular calcification due to its role as a source of PPi 2 and as a direct inhibitor of CPC formation. Two families of sodium phosphate co-transporters have been principally identified, Type II and Type III, which have high affinity for HPO 4 2− and H 2 PO 4 − , respectively. Type II family comprises three members, which are expressed in small intestine (NaPi-IIb) and kidneys (NaPi-IIa and NaPi-IIc), two important sites for the control of phosphate homeostasis. Moreover, type-III family is represented by Pit-1 and Pit-2, which mediates the movement of Pi ions across the cell membrane and are ubiquitously expressed. Expression of Pit-1 is higher in VSMCs 12 and plays a critical role in cartilage calcification and regulation of apoptosis and cell proliferation. 13 Expression of Pit-2 is higher in the VSMC, liver, heart, and brain. 12, 14 In recent studies, an association has been found between loss-of-function of Pit-2 and familial idiopathic basal ganglia calcification in humans and mice. 14 Targeted deletion of Pit-1 in VSMCs in mouse did not induce aortic calcification due to compensatory regulation by Pit-2. 15 Moreover, loss of equilibrative nucleoside transporter 1 (ENT1, SLC29A1), a transporter of adenosine into cells, produces ectopic calcification of spinal tissues. 16 Extracellular PPi metabolism cycle begins with the transport of ATP to extracellular space (Figure 2) . Adenosine-5 ′ -triphosphate released by cells occurs through at least two mechanisms: (i) via exocytotic mechanisms and (ii) via pump/channels. 17 Finally, progressive ankylosis (ANK) gene was initially identified to play an important role in vascular and joint calcifications as a PPi pump. 18 However, additional studies have shown that mutations in the channel core of ANK cause craniometaphyseal dysplasia, induces the formation of calcium phosphate crystal (CPC), mainly hydroxyapatite. Extracellular pyrophosphate (PPi) is the major endogenous inhibitor of CPC deposition that is degraded by tissue non-specific alkaline phosphatase (TNAP) and produced during extracellular hydrolysis of adenosine-5 ′ -triphosphate (ATP), via ectonucleotide pyrophosphatase phosphodiesterase 1 (eNPP1). AMP is degraded by ecto-5 ′ nucletotidase (CD73) to form adenosine (Ado) and Pi. To generate ATP by mitochondria or another metabolic pathway, Ado and Pi are recovered from the extracellular space by equilibrative nucleoside transporter 1 (ENT1) and sodium phosphate transporter (Pit1 and Pit2), respectively. To close the cycle of extracellular ATP metabolism, ATP is released by cells via exocytotic mechanisms and via multiple types of membrane pump/channels. eNPP1, ENT1, Pit2, and CD73 induce ectopic calcification by loss of its function and also the dysfunction of ATP synthesis. Tissue non-specific alkaline phosphatase induces calcification by increases of its activity. Phosphate, pyrophosphate and vascular calcification metabolism regulating its enzymes (eNPP1, TNAP), transporters (Pits, ENT1), and ATP efflux (Figure 2 ).
Perspective
Phosphate-induced VC has been widely used as an in vitro model of calcification. This model induces, in VSMCs, a profound transition to a bone-forming phenotype, which was logically interpreted as a consequence of Pi uptake. 3 However, in support to old observations, it has been shown that CPC formation is a passive physicochemical process that does not require any cellular activity. 7 Moreover, different studies have shown that, in VSMCs, CPC can induce the same transition to a bone-forming phenotype that we observed in Pi-induced VC. 21 This suggests that the active mechanisms described could be a response to the ectopic calcification. 7 
Clinical conclusion
The balance between Pi and PPi, which is strictly controlled by a complex interplay of genes, plays an undisputed role in VC ( Figure 3 ). We should focus our studies in understanding the phosphate and pyrophosphate homeostasis for predicting and designing therapeutic strategies ( Figure 3 ). These include phosphate binders in combination with restriction of Pi intake, 4 both currently used in clinical practice to reduce Pi plasma levels. Moreover, in order to increase PPi availability, the administration of exogenous PPi, alone or in combination with alkaline phosphatase inhibitors, should be used.
